Advertisement

AAPS PharmSciTech

, Volume 17, Issue 3, pp 673–681 | Cite as

Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement

Research Article

Abstract

The aim of the present work was to prepare a co-amorphous mixture (COAM) of Nateglinide and Metformin hydrochloride to enhance the dissolution rate of poorly soluble Nateglinide. Nateglinide (120 mg) and Metformin hydrochloride (500 mg) COAM, as a dose ratio, were prepared by ball-milling technique. COAMs were characterized for saturation solubility, amorphism and physicochemical interactions (X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR)), SEM, in vitro dissolution, and stability studies. Solubility studies revealed a sevenfold rise in solubility of Nateglinide from 0.061 to 0.423 mg/ml in dose ratio of COAM. Solid-state characterization of COAM suggested amorphization of Nateglinide after 6 h of ball milling. XRPD and DSC studies confirmed amorphism in Nateglinide, whereas FTIR elucidated hydrogen interactions (proton exchange between Nateglinide and Metformin hydrochloride). Interestingly, due to low energy of fusion, Nateglinide was completely amorphized and stabilized by Metformin hydrochloride. Consequently, in vitro drug release showed significant increase in dissolution of Nateglinide in COAM, irrespective of dissolution medium. However, little change was observed in the solubility and dissolution profile of Metformin hydrochloride, revealing small change in its crystallinity. Stability data indicated no traces of devitrification in XRPD of stability sample of COAM, and % drug release remained unaffected at accelerated storage conditions. Amorphism of Nateglinide, proton exchange with Metformin hydrochloride, and stabilization of its amorphous form have been noted in ball-milled COAM of Nateglinide-Metformin hydrochloride, revealing enhanced dissolution of Nateglinide. Thus, COAM of Nateglinide-Metformin hydrochloride system is a promising approach for combination therapy in diabetic patients.

KEY WORDS

COAM dose ratio improved Nateglinide dissolution Metformin hydrochloride Nateglinide 

INTRODUCTION

Drug safety and therapeutic efficacy are critical concerns of the bioavailability of drugs. Thus, poor solubility and subsequently poor oral bioavailability of a drug have become a major challenge in the formulation industry (1,2). The current scenario reveals abundant research carried out on the amorphization of drugs, a state which possesses high thermodynamic energy and significantly improved “apparent” solubility. However, such a structurally disordered metastable form causes free molecular mobility and enhanced chemical reactivity too (3). Therefore, stabilization of the amorphous form is a vital issue as the thermodynamic drive is preordained towards devitrification during the manufacturing process and shelf life of the product (4,5).

In order to stabilize amorphous drugs, solid polymeric dispersions have been widely attempted and extensive literature is available on the mechanism of drug-polymer dispersions, molecular interactions therein, and subsequent stabilization (6, 7, 8). In some cases, the use of polymers may inhibit the re-crystallization of drugs by increasing glass transition temperature (Tg) as compared to a pure amorphous drug (9,10). It is also assumed that molecular interactions between drug and polymer play an important role in stabilization of the drug. However, amorphous dispersions of drug-polymer are typically hygroscopic, and the absorbed moisture can reduce the Tg of the dispersion followed by re-crystallization of the drug (11). Manufacturing of aforesaid dispersions is critical due to the amount of polymers involved and limited miscibility of drugs into polymers leading to a bulkier dosage form (12,13).

Binary co-amorphous mixture formation has been extensively studied for a decade towards the stabilization of amorphous drugs, which includes the use of small molecules like saccharine, amino acids, citric acid, and sugars (14, 15, 16). Firstly, binary amorphous mixtures of two drugs were reported by Yamamura et al. (17) for cimetidine and indomethacin, in which the amorphous precipitates were obtained by solvent evaporation method. Recently, Rade et al. have developed co-amorphous binary mixtures of various drugs viz indomethacin-ranitidine hydrochloride (18), in which it has been concluded that both indomethacin and ranitidine hydrochloride were fully converted into the amorphous state through molecular interaction after co-milling in contrast to the partially crystalline form of individually milled drugs. In contrast, the simvastatin-glipizide co-amorphous mixture showed improved physical stability without evidence of intermolecular interactions as studied by Lobmann et al. (19). Alleso et al. have illustrated the stabilization of the naproxen-cimetidine amorphous mixtures dictated by molecular-level interactions rather than bulk-level phenomena (20). Therefore, there is a hope and need to rationalize the co-amorphous concept by using a specific clinical dose ratio of pharmacologically relevant drug combinations.

In this present work, an attempt has been made to prepare co-amorphous mixture (COAM) of Nateglinide (NT) and Metformin hydrochloride (MT) in their clinical dose ratio. NT is an oral blood-glucose-lowering agent belonging to the class meglitinides, a class II drug of the Biopharmaceutics Classification System (BCS), having poor solubility of about 0.008 mg/ml and high permeability (log P, 4.2) (21,22). On the contrary, MT (BCS III) shows solubility in the range of 300 mg/ml over the entire pH range of 1–6.8 (23). Several studies have been reported for improving solubility of NT including nanoparticles, solid dispersion, and liquisolid system (22,24,25).

Clinically, combination therapy of oral hypoglycemic agents is reasonable, aiming to minimize side effects with the additional benefit of reduction in the cost of therapy. The combination of NT and MT is rational because it works synergistically in patients whose hyperglycemia is not controlled by monotherapy, and interestingly, its co-administration does not affect the pharmacokinetics of either drug (26,27).

In existing work, mechanically activated (ball-milling) co-amorphization of anti-diabetic agents NT and MT has been attempted, aiming at improvement in the dissolution of NT. From the manufacturing viewpoint, ball milling is a green technology and is superior to solvent approaches (28). In this study, NT and MT are ball milled in varying ratios in order to check the feasibility of co-amorphization. Taking into account dosage regimen of both drugs, 120 mg of NT and 500 mg of MT, in same dose ratio, study has been carried out further. The degree of amorphization has been investigated by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and SEM studies. Additionally, physical stability and in vitro dissolution studies have been performed to ensure improved dissolution of NT.

MATERIALS AND METHODS

Materials

Nateglinide has been provided as a gift sample by Cipla Ltd., Goa, India, and Metformin hydrochloride was gifted by Sanofi Ltd., Gujrat, India. The chemical structure of both drugs used in the present study is shown in Fig. 1. All other reagents used in the study were of analytical grade.
Fig. 1

Molecular structures of a Nateglinide and b Metformin hydrochloride

Methods

Ball Milling

Nateglinide and Metformin hydrochloride were milled together to prepare COAM using a ball mill (Scientific Engineering Corporation, India, Model- Secor 141 v.s.) having a stainless steel cylindrical jar. One gram of NT and MT mixture, at 1:1, 1:3, 1:5, and dose ratio (120 mg: 500 mg), was ball milled using 9 mm stainless steel balls at ambient temperature with 40 RPM. Trials were taken for optimization of ball-milling time of COAM till 6 h. The crystalline drugs were also ball milled separately for comparison at the same milling parameters. Physical mixtures (PM) were prepared by triturating crystalline NT and MT with a mortar and pestle for 10 min in similar proportions. All the samples were stored in a desiccator until further use.

Saturation Solubility Studies

The solubility of NT, MT, and COAM was determined by adding known excess samples to 5 ml of water and a respective buffer (buffer pH 1.2, pH 4.5, pH 6.8, pH 7.5) separately, and samples were shaken on an orbital shaker for 48 h at 37°C (29). Samples were further centrifuged at 7000 RPM for 10 min, and supernatant was filtered through a 0.45-μm membrane filter. Drug content was determined by HPLC (Agilent model-1220 infinity HPLC, with autosampler, a diode array and multiple wavelength detector, and OpenLab software). A Hypersil ODS C18 (250 × 4.6 mm), Thermo Fisher Scientific, USA, column was used for the study. For simultaneous analysis of NT and MT, the HPLC method was developed and validated with respect to linearity, accuracy, precision, and robustness at our end. For the HPLC method, the mobile phase consisted of methanol and phosphate buffer pH 3.0 (pH adjusted with dilute ortho-phosphoric acid) in the ratio of 75:25, with flow rate 0.8 ml/min, injection volume 20 μl, and detection wavelength 216 nm being used. The study was performed in triplicate, and results were averaged.

X-ray Powder Diffraction (XRPD)

X-ray powder diffraction studies were performed for samples using an Xpert Pro MPD X-ray Diffractometer (Panalytical, Netherlands) through Xcelerator Detector with diffracted beam monochromator (k = 1.5405 Å). Samples were scanned between 0 and 70° (2θ) using an acceleration voltage and current of 40 kV and 40 mA, respectively. The principle peaks and intensity data were collected and analyzed using the software WINPLOTR (Panalytical, Netherlands). All samples of crystalline and ball-milled NT, MT, and COAM were separately studied by XRPD.

Differential Scanning Calorimetry (DSC)

Differential scanning calorimetry study was carried out on model DSC 6220 (SII Nanotechnology, SEIKO, Japan). Calibration of the DSC instrument was carried out using indium as reference standard. DSC thermograms were obtained under a nitrogen gas flow of 80 ml/min at a rate of 10°C/min of all fresh ball-milled mixtures and active pharmaceutical ingredient (API). Approximately 3 to 5 mg of samples was crimped in an aluminum pan and heated at a rate of 10°C/min from 10 to 350°C. Crystallinity calculation of drugs in the COAM was performed using the following equation given by Rawlinson et al. (30):
$$ \%\mathrm{Crystallinity}=\frac{\Delta \mathrm{HmCOAM}}{\Delta \mathrm{HmDrug}\times W}\times 100 $$

Where ∆HmCOAM is the enthalpy of the COAM (mJ/mg) and ∆HmDrug is the enthalpy of drug (mJ/mg) and W is the weight fraction of drug in COAM.

Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectra of NT, MT, PM, and ball-milled samples were recorded using an infrared spectrophotometer, model- Spectrum Rx1 (Perkin Elmer, USA) to evaluate possible molecular interactions between the NT and MT. Approximately 2- to 3-mg samples were ground thoroughly with KBr and mixed uniformly, and the spectra were recorded at a spectral resolution of ±4 cm−1 over a range of 400–4000 cm−1. Triplicate scan of each sample was taken.

Scanning Electron Microscopy

Scanning electron microscope, ZEISS Ultra FE-SEM (Germany), was used to obtain scanning electron microphotographs of NT, MT, PM, and COAM. An accelerating voltage of 15 kV was used. Before taking a microphotograph, the samples were coated with gold under an argon atmosphere using a sputter coater Emitech K-100× (Quorum Technologies Ltd, UK).

In Vitro Dissolution Studies

In vitro drug release studies were performed for NT and COAM using USP type I dissolution test apparatus (Electrolab, India) for 1 h with a speed of 100 RPM and 900 ml of water and pH 1.2 buffer or phosphate buffer pH 6.8 as a dissolution medium (multimedia dissolution study) at 37°C. One hundred milligrams of samples of the COAM were placed in the basket, and 5 ml aliquots were withdrawn at specific time intervals, and the same amount of volume was replaced with fresh dissolution medium. The samples were analyzed using above described HPLC method. The experiments were conducted in triplicate, and analysis of data was carried out using PCP disso V3 software (Bharati Vidyapeeth, Poona College of Pharmacy, Pune, India).

Stability Studies

For stability studies, COAM samples were stored in a stability chamber (Thermolab Scientific Equipments Pvt. Ltd., India) at 40°C/75°C condition and ambient temperature for 45 days and were periodically removed at 30 and 45 days and evaluated for physical appearance, XRPD, and in vitro dissolution. Further, COAM samples were characterized for drug content by HPLC analytical method given in the “Saturation Solubility Studies” section.

RESULTS

Ball Milling and Saturation Solubility Studies

The experimentally determined solubility of NT, physical mixture, and COAM in purified water have been given in Table I. The pH-solubility profile revealed that NT shows pH-dependant solubility which gradually increases from acidic pH to alkaline pH as shown in Fig. 2. Preliminary studies have shown linear rise in the solubility of COAM as the quantity of MT increases in the COAM containing 1:1, 1:3, dose ratio, and 1:5. It has been depicted that increase in ball-milling time shows gradual rise in the solubility of NT till 240 min. It is evident from solubility studies that MT possesses free solubility in the overall physiological pH range, and there is no statistically significant difference observed in the COAM form.
Table I

Solubility Study of NT

Description of API/formulation

Solubility in water (mg/ml)

Crystalline

0.061

Ball milled

0.106

NT:MT (1:1 ratio)

0.346

NT:MT (1:3 ratio)

0.396

NT:MT (1:5 ratio)

0.531

NT:MT (Dose ratio)

0.423

NT:MT physical mixture (dose ratio)

0.195

API active pharmaceutical ingredient, NT Nateglinide, MT Metformin hydrochloride

Fig. 2

pH solubility profile of NT

X-ray Powder Diffraction (XRPD)

Diffractograms of NT shows distinct peaks of crystallinity at 13.5°, 16.5°, 19.5°, and 24° and for MT at 17°, 22°, 28°, 30°, and 37° (Fig. 3). The XRPD pattern of COAM showed a reduction in the peak intensity for both drugs within the first 2 h of ball milling which further decreased after 4 h of ball milling. When the ball-milling duration was extended up to 6 h, the characteristic peaks of NT completely disappeared for all API ratios, demonstrating conversion to amorphous form; however, low-intensity peaks of MT were seen in COAM. Similarly, when the drugs were separately ball milled for 6 h under same ball-milling conditions, enhanced amorphism was noted in NT, compared to MT. Relatively, the rate of amorphization of NT was faster than MT in COAM.
Fig. 3

X-ray powder diffractogram for a crystalline MT, b ball-milled MT, c crystalline NT, d ball-milled NT, e COAM of dose ratio at 6 h, f COAM of dose ratio at 4 h, g COAM of dose ratio at 2 h, and h COAM at 40°/75% RH for 45 days

Differential Scanning Calorimetry (DSC)

The DSC thermogram of NT and MT showed endothermic transition peaks corresponding to their melting points at 131°C and 235°C, suggesting the presence of polymorph B for NT and polymorph A for MT. In PM, NT and MT peaks were seen at their melting points as anticipated. However, the enthalpy of both NT and MT has been reduced from 29.8 to 6.8 mJ/mg and 389 to 291 mJ/mg, respectively, in PM. Interestingly, the melting endotherm for NT has almost disappeared, and the endothermic peak for MT was shifted to 221–225°C from 235°C in all ratios of COAM. This supports total disappearance of XRPD peaks of NT, as aforesaid. The % crystallinity data was calculated for NT and MT in COAM sample which shows complete amorphization of NT and 63% crystallinity of MT in COAM. The thermogram details for aforesaid discussion can be seen in Fig. 4.
Fig. 4

DSC thermogram of a crystalline NT, b crystalline MT, c physical mixture of NT and MT, d COAM of 1:1 ratio, e COAM of 1:3 ratio, and f COAM of dose ratio

Fourier Transform Infrared Spectroscopy

FTIR spectra of individual drugs and mixtures thereof have been given in Fig. 5. The characteristic bands of NT were observed at the wave numbers of 1209–1384 cm−1 justifying the presence of carboxyl and carboxylate groups. In addition to this peak, C-H stretching between 2867 and 3030 cm−1, C=O vibration at 1742 cm−1, and the C–NH bending vibration (amide band II) at 1540 cm−1 were also seen in the NT spectrum. Similarly, characteristic bands of MT were observed including N-H stretching (primary and secondary) vibrations at wave number 3371 and 3173 cm−1. Furthermore, N-H deformation vibrations at 1623–1577 cm−1 and C-N stretching vibration at 1057–1030 cm−1 were also observed in the MT spectrum. Comparison of FTIR spectra of crystalline NT, MT, and COAM revealed slight broadening of peaks at the 1750- to 1700-cm−1 region of COAM as compared to pure drugs.
Fig. 5

Fourier transform infrared spectra of a crystalline NT, b crystalline MT, c COAM of 1:1 ratio, d COAM of 1:3 ratio, and e COAM of dose ratio

Scanning Electron Microscopy

Prior to milling, needle-shaped, long, and slender crystals of different sizes were seen in the NT samples, while irregular-shape crystals were observed in the MT samples, as seen in Fig. 6. COAM showed small spheres without any traces of needle-shape crystals ensuring the possibility of instantaneous formation of microstructured particles dispersed in the MT matrix, wherein ordered needle geometry has been lost. Microphotograph of PM as raw material showed mixed irregular and needle structures indicating existence of original form of both API.
Fig. 6

SEM of a crystalline NT, b crystalline MT c COAM of dose ratio and d physical mixture of MT and NT

In- Vitro Dissolution Studies

Comparison of in vitro dissolution (water media) profiles of crystalline NT, ball-milled NT, physical mixture, and COAM of dose ratio revealed that crystalline and ball-milled API showed very slow drug release rate whereas physically mixed NT and MT resulted in a further improvement in the release rate as seen in Fig. 7. However, it hindered the drug release over 49.65% at 60 min. COAM of dose ratio exhibited superior dissolution profile in water than the physical mixture and crystalline/ball-milled NT.
Fig. 7

In vitro dissolution profile of NT

Multimedia drug release profiles of crystalline NT, PM, and COAM are illustrated in Fig. 8. Drug release of COAM was significantly higher (P < 0.05) in pH 1.2 buffer as compared to crystalline NT or PM. However, there was no major change observed in drug release of PM and COAM at higher pH dissolution medium, precisely in phosphate buffer pH 6.8, at the end of 60 min (Fig. 8). Predictably, Metformin hydrochloride release remained unaffected in multimedia dissolution, and more than 95% drug release was observed of crystalline API and in COAM form.
Fig. 8

In vitro multimedia dissolution profiles of NT, PM, and COAM

Stability Studies

X-ray powder diffractograms of sample subject to stability studies have shown no characteristic peaks of NT at 40°C/75°C for 45 days as seen in Fig. 3(H). As partial amorphism was attained for MT initially, low-intensity peaks of MT have been observed in the diffractogram. The in vitro dissolution studies also showed satisfactory dissolution profile matching to the initial samples as shown in Fig. 8. Besides, it was also noted that COAM remained as a white to off-white free-flowing powder without changing its physical appearance on stability. Drug content was found in the accepted range of 96.4–98.3%w/w for NT and 98.2–99.6%w/w for MT which was similar to the initial values for both API.

DISCUSSION

In the present study, the combination of NT and MT has been co-processed in dose ratio by ball milling to form a COAM. It has been reported that induction of amorphism by mechanical activation can be related to the milling time and intensity (18,31). Hence, ball-milling time was optimized, and a steady rise in the solubility of NT was observed till 240 min. Thereafter, further lengthening the ball-milling duration does not show any noteworthy change in the solubility of COAM.

The pH-dependant solubility of NT at the physiological pH range can be attributed to the anionic nature of NT (pKa value 3.1). NT exists predominantly in un-ionized form at the acidic pH of the stomach which causes very low solubility of a drug, whereas higher physiological pH causes complete ionization of the carboxylic group and improved solubility to a large extent (32,33). Result suggests that each NT molecule may be interacting with more than one MT molecule and thereby increases the solubility of NT with the rise in quantities of MT. Thus, increase in the solubility would result in increased dissolution rate of NT and would resolve the problem of low bioavailability. Being a BCS class III drug, MT shows free solubility in all forms.

Solubility data of COAM is further supported by XRPD studies which reveal a steady decrease in peak intensity of NT with time and after 6 h complete amorphization of NT has been attained in COAM. This means a decrease in crystallinity of NT leads to improved solubility. On the other hand, partial amorphization of MT was observed which can be contributed to its higher quantity in dose ratio of COAM. Surprisingly, NT alone could not be completely transformed into its amorphous solid form upon ball milling. This can be explained with Nateglinide structural conformation, stabilized through intramolecular hydrogen bonds as reported by Bharatam et al. (34). Similar observations have also been reported by Chieng et al. for indomethacin-ranitidine hydrochloride in which individual drugs retained partial crystallinity after co-milling under the same conditions (18).

DSC output had revealed miscibility of NT and MT into COAM in addition to the amorphization shown by XRPD studies. And, a little shift in the melting endotherm with reduction in enthalpy of fusion 221–237 J/g has been noted for MT, which is an indicator of molecular-level interaction between NT and MT, which even confirms partial amorphism of MT in COAM. Early amorphization of NT can be attributed to its comparatively small amount of enthalpy, than MT. This observation has also been backed up by % crystallinity data, which confirms retention of crystallinity of MT in COAM and no evidence of crystalline NT.

For better understanding of interactions between NT and MT, molecular structures of both have been depicted in Fig. 1. NT has two strong proton acceptors and donors each, whereas MT has four proton acceptors and five donors, enabling hydrogen interactions between both drugs. Thus, hydrogen bonding is responsible for molecular interaction between NT and MT which further influences the arrangement of molecules in the COAM (34,35). Generally, band shift and band broadening have been observed in the transformation of crystalline to amorphous compounds (36). Furthermore, specific changes are indicators of hydrogen bonding between both drugs from the vibration regions of the hydrogen-bonded carboxylic acid moiety (1750- to 1700-cm−1 region), showing prominent broadening of spectra. Thus, IR spectra confirmed physical interaction between NT and MT, in PM and COAM.

Consequently, SEM microphotographs also support findings of XRPD and DSC data and amorphization of NT. Therefore, it is possible that complete disappearance of crystalline NT due to physical contact with the hydrophilic MT may be responsible for the enhanced drug solubility of the COAM.

Faster drug release rate of COAM in contrast to crystalline NT cannot be explained merely by particle-size changes during the ball-milling process but can be attributed to an amorphous form of drug. As shown by Löbmann et al., binary co-amorphous drug mixtures formed through molecular interactions lead to synchronized, specifically pairwise, dissolution (37). Thus, it can be proposed in effect that the heterodimer of NT-MT is released instead of the individual drug. It has been also hypothesized that the wettability of small lipophilic NT particles was further improved in the presence of highly soluble MT (38,39).

Selection of an appropriate dissolution medium should be based on drug characteristics and formulation features which can clearly discriminate the variations in release profile (40,41). The pH-solubility profile suggested that very low solubility of NT in the pH 1.2 buffer may lead to the precipitation of NT in the acidic environment of the stomach. Therefore, pH 1.2 buffer has been used as a pH-simulated medium for dissolution of crystalline NT, PM, and COAM as shown in Fig. 8. Moreover, dissolution parameters should also consider pH at the site of absorption for the drugs showing pH-dependent solubility (42, 43, 44). Higher NT release into the pH 1.2 buffer in COAM form is particularly encouraging because dissolution is going to be a rate-limiting step particularly in the acidic pH of the stomach for immediate release formulations of NT (45,46). However, there was no major difference observed in the drug release of PM and COAM at a higher pH dissolution medium, precisely in phosphate buffer pH 6.8, at the end of 60 min (Fig. 8). This observation was in line with the higher solubility of NT in alkaline pH. MT has showed almost complete drug release irrespective of dissolution medium. The results were well anticipated and can be credited to its free solubility (47).

Thus, XRPD spectra indicate absence of devitrification for NT in COAM and suggest the stabilization of amorphous NT by MT. Stability samples do not show any difference in in vitro dissolution studies supporting the stabilization of amorphous NT. In addition, physicochemical stability of COAM has been substantiated by the unaffected physical appearance and drug content. Hence, as stated above, the increased stability and enhanced dissolution in COAM can be contributed to molecular interactions between NT and MT (48,49).

CONCLUSION

Nateglinide and Metformin hydrochloride have been transformed into a co-amorphous state by a simple, green, economic ball-milling process. In co-amorphous form, the non-bonding type of interactions (proton exchange) between NT and MT has significantly increased the drug release rate for Nateglinide in COAM. Hence, the combination therapy of both drugs in the form of COAM appears to be an excellent option for chronic therapy of type 2 diabetes. Thus, the role of co-amorphism can be further investigated for fixed-dose combinations of drugs available clinically.

Notes

Acknowledgments

Authors are also thankful to Tata Institute of Fundamental Research (TIFR), India, for assistance on XRPD and SEM analysis.

Conflict of Interest

The authors declare that they have no competing interests.

References

  1. 1.
    Hoerter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Delivery Rev. 1997;25:3–14.CrossRefGoogle Scholar
  2. 2.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:3–25.CrossRefGoogle Scholar
  3. 3.
    Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharm. 2008;5(6):905–20. doi: 10.1021/mp800092t.CrossRefPubMedGoogle Scholar
  4. 4.
    Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;4:27–42.CrossRefGoogle Scholar
  5. 5.
    Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282(1–2):151–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Noolkar SB, Jadhav NR, Bhende SA, Killedar SG. Solid-state characterization and dissolution properties of Meloxicam–Moringa Coagulant–PVP ternary solid dispersions. AAPS Pharm Sci Tech. 2013;14(2):569–77. doi: 10.1208/s12249-013-9941–5.CrossRefGoogle Scholar
  7. 7.
    Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm Res. 2005;22(10):1727–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Sun Y, Zhu L, Wu T, Cai T, Gunn EM, Yu L. Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives. AAPS J. 2012;14(3):380–8. doi: 10.1208/s12248-012-9345-6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hancock B, Shamblin S, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12(6):799–806.CrossRefPubMedGoogle Scholar
  10. 10.
    Pokharkar V, Mandpe L, Padamwar M, Ambike A, Mahadik K, Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006;167:20–5. doi: 10.1016/j.powtec.2006.05.012.CrossRefGoogle Scholar
  11. 11.
    Hancock B, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res. 1994;11(4):471–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises and recent breakthroughs. J Pharm Sci. 1999;88(10):1058–66.CrossRefPubMedGoogle Scholar
  13. 13.
    Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 2013;453(1):65–79. doi: 10.1016/j.ijpharm.2012.04.066.CrossRefPubMedGoogle Scholar
  14. 14.
    Gao Y, Liao J, Qi X, Zhang J. Coamorphous repaglinide–saccharin with enhanced dissolution. Int J Pharm. 2013;450(1–2):290–5. doi: 10.1016/j.ijpharm.2013.04.032.CrossRefPubMedGoogle Scholar
  15. 15.
    Lobmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs - Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm. 2013;85(3 Pt B):873–81. doi: 10.1016/j.ejpb.2013.03.014.CrossRefPubMedGoogle Scholar
  16. 16.
    Masuda T, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H, Terada K. Cocrystallization and amorphization induced by drug–excipient interaction improves the physical properties of acyclovir. Int J Pharm. 2012;422:160–9. doi: 10.1016/j.ijpharm.2011.10.046.CrossRefPubMedGoogle Scholar
  17. 17.
    Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Physicochemical properties of amorphous precipitates of cimetidine–indomethacin binary system. Eur J Pharm Biopharm. 2000;49:259–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Chieng N, Aaltonen J, Saville D, Rades T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur J Pharm Biopharm. 2009;71:47–54. doi: 10.1016/j.ejpb.2008.06.022.CrossRefPubMedGoogle Scholar
  19. 19.
    Lobmann K, Strachan C, Grohqanz H, Rades T, Korhonen O, Laitinen R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81:159–69. doi: 10.1016/j.ejpb.2012.02.004.CrossRefPubMedGoogle Scholar
  20. 20.
    Alleso M, Chieng N, Rehder S, Rantanen J, Rades T, Aaltonen J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J Control Release. 2009;136(1):45–53. doi: 10.1016/j.jconrel.2009.01.027.CrossRefPubMedGoogle Scholar
  21. 21.
    McLeod J. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet. 2004;43(2):97–120.CrossRefPubMedGoogle Scholar
  22. 22.
    Maggi L, Bruni G, Maietta M, Canobbio A, Cardini A, Conte U. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing. Int J Pharm. 2013;454:562–7. doi: 10.1016/j.ijpharm.2013.06.084.CrossRefPubMedGoogle Scholar
  23. 23.
    Desai D, Wong B, Huang Y, Ye Q, Tang D, Guo H, et al. Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity. J Pharm Sci. 2014;103(3):920–6. doi: 10.1002/jps.23852.CrossRefPubMedGoogle Scholar
  24. 24.
    Reddy MKK, Rao BN, Reddy KR. Study on effect of excipients in enhancing the solubility of nateglinide by solid dispersions. Asian J Pharm Tech. 2012;2(1):04–7.Google Scholar
  25. 25.
    Mokale V, Naik J, Patil K, Chaudhari R, Khairnar G. Enhancement of solubility with formulation & in-vitro evaluation of oral nateglinide compacts by liquisolid technique. Advances Diabetes Metabolism. 2013;1(3):57–64.Google Scholar
  26. 26.
    Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of Nateglinide and Metformin. Diabetes Care. 2000;23(3):349–53.CrossRefPubMedGoogle Scholar
  27. 27.
    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Einfal T, Planinsek O, Hrovat K. Methods of amorphization and investigation of the amorphous state. Acta Pharm. 2013;63:305–34. doi: 10.2478/acph-2013-0026.CrossRefPubMedGoogle Scholar
  29. 29.
    The United States Pharmacopoeia and the National Formulary. 37th ed. Unites States Pharmacopoeia Convention; 2014.Google Scholar
  30. 30.
    Rawlinson CF, Williams AC, Timmins P, Grimsey I. Polymer-mediated disruption of drug crystallinity. Int J Pharm. 2007;336:42–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Mura P, Cirri M, Faucci MT, Ginès-Dorado JM, Bettinetti GP. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal. 2002;30(2):227–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Remko M. Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. J Mol Struc: Theochem. 2009;897(1–3):73–82.CrossRefGoogle Scholar
  33. 33.
    Okamura A, Emoto A, Koyabu N, Ohtani H, Sawada Y. Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT 1. Br J Pharmacol. 2002;137:391–99.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Jain V, Dhaked DK, Kasetti YP, Bharatam V. Computational study on the conformational preferences in nateglinide. J Phys Org Chem. 2012;25(8):649–57. doi: 10.1002/poc.1956.CrossRefGoogle Scholar
  35. 35.
    Bhende S, Jadhav N. Moringa coagulant as a stabilizer for amorphous solids: part I. AAPS PharmSciTech. 2012;13(2):400–10. doi: 10.1208/s12249-012-9755-x.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Heinz A, Strachan CJ, Gordon KC, Rades T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol. 2009;61(8):971–88. doi: 10.1211/jpp/61.08.0001.CrossRefPubMedGoogle Scholar
  37. 37.
    Lobmann K, Laitinen R, Grohqanz H, Gordon KC, Rades T. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8:1919–28. doi: 10.1021/mp2002973.CrossRefPubMedGoogle Scholar
  38. 38.
    Biazar E, Beitollahi A, Rezayat SM, Forati T, Asefnejad A, Rahimi M, et al. Effect of the mechanical activation on size reduction of crystalline acetaminophen drug particles. Int J Nanomedicine. 2009;4:283–7.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Zhang F, Aaltonen J, Tian F, Saville DJ, Rades T. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur J Pharm Biopharm. 2009;71(1):64–70. doi: 10.1016/j.ejpb.2008.07.010.CrossRefPubMedGoogle Scholar
  40. 40.
    Anand O, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13(3):328–35. doi: 10.1208/s12248-011-9272-y.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Tang L, Khan SU, Muhammad NA. Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm Dev Technol. 2001;6(4):531–40.CrossRefPubMedGoogle Scholar
  42. 42.
    Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res. 2002;19(3):345–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Chrzanowski F. Preformulation considerations for controlled release dosage forms: part II-selected candidate support. AAPS PharmSciTech. 2008;9(2):639–45. doi: 10.1208/s12249-008-9067-3.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Raju V, Murthy KVR. Development and validation of new discriminative dissolution method for Carvedilol tablets. Indian J Pharm Sci. 2011;73(5):527–36. doi: 10.4103/0250-474X.99000.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm. 2011;79(2):349–56. doi: 10.1016/j.ejpb.2011.04.005.CrossRefPubMedGoogle Scholar
  46. 46.
    Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem. 2001;1(4):277–351.CrossRefPubMedGoogle Scholar
  47. 47.
    Bretnall AE, Clarke GS. Metformin hydrochloride. In: Florey K, editor. Analytical profiles of drug substance. New York: Academic; 1998. p. 243–91.Google Scholar
  48. 48.
    Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Investigation of properties and recrystallization behaviour of amorphous indomethacin samples prepared by different methods. Int J Pharm. 2011;417(1–2):94–100. doi: 10.1016/j.ijpharm.2010.12.019.CrossRefPubMedGoogle Scholar
  49. 49.
    Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci. 2001;12(3):261–9.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2015

Authors and Affiliations

  1. 1.Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMSMumbaiIndia

Personalised recommendations